242 14-Day, High-Dose Acid Suppression, Non-Bismuth Quadruple Therapies (Hybrid vs. Concomitant) for Helicobacter pylori Infection: A Randomized Trial

Molina–Infante, Javier; Romano, Marco; Bermejo, Miguel Fernández; Federico, Alessandro Di; Gravina, Antonietta Gerarda; Pozzati, Liliana; Abadia, Elena Garcia; Martínez-Alcalá, Carmen; Miranda, Agnese; Rodriguez, Gema Vinagre; Alonso, Moises Hernandez; Gallardo, Belen Perez; Medina, Francisco J. Rancel; Cuadrado, Marta Gata; Gisbert, Javier P.

doi:10.1016/s0016-5085(13)60188-2

Cited by 6 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The hybrid regimens consist of dual therapy with a PPI and amoxicillin for 7 days, with addition of a concomitant quadruple therapy with a PPI, amoxicillin, clarithromycin and metronidazole for another 7 days. The eradication rate was excellent with 99% in PP and 97% in the ITT analysis, even in dual clarithromycin and metronidazole resistance strains . A tendency towards better results seems to be the result of extended use of amoxicillin for 14 days, compared to sequential or concomitant therapy.…”

Section: Antibiotic Therapeutic Regimensmentioning

confidence: 90%

“…The eradication rate was excellent with 99% in PP and 97% in the ITT analysis, even in dual clarithromycin and metronidazole resistance strains. 168 A tendency towards better results seems to be the result of extended use of amoxicillin for 14 days, compared to sequential or concomitant therapy. One randomised clinical trial indicated that the hybrid therapy had equivalent eradication rates to 14-day concomitant therapy.…”

Section: Antibiotic Therapeutic Regimensmentioning

confidence: 99%

See 1 more Smart Citation

Review article: the global emergence ofHelicobacter pyloriantibiotic resistance

Thung

Aramin

Vavinskaya

et al. 2015

Aliment Pharmacol Ther

619

562

View full text Add to dashboard Cite

SummaryBackground Helicobacter pylori is one of the most prevalent global pathogens and can lead to gastrointestinal disease including peptic ulcers, gastric marginal zone lymphoma and gastric carcinoma.AimTo review recent trends in H. pylori antibiotic resistance rates, and to discuss diagnostics and treatment paradigms.MethodsA PubMed literature search using the following keywords: Helicobacter pylori, antibiotic resistance, clarithromycin, levofloxacin, metronidazole, prevalence, susceptibility testing.ResultsThe prevalence of bacterial antibiotic resistance is regionally variable and appears to be markedly increasing with time in many countries. Concordantly, the antimicrobial eradication rate of H. pylori has been declining globally. In particular, clarithromycin resistance has been rapidly increasing in many countries over the past decade, with rates as high as approximately 30% in Japan and Italy, 50% in China and 40% in Turkey; whereas resistance rates are much lower in Sweden and Taiwan, at approximately 15%; there are limited data in the USA. Other antibiotics show similar trends, although less pronounced.ConclusionsSince the choice of empiric therapies should be predicated on accurate information regarding antibiotic resistance rates, there is a critical need for determination of current rates at a local scale, and perhaps in individual patients. Such information would not only guide selection of appropriate empiric antibiotic therapy but also inform the development of better methods to identify H. pylori antibiotic resistance at diagnosis. Patient‐specific tailoring of effective antibiotic treatment strategies may lead to reduced treatment failures and less antibiotic resistance.

show abstract

Section: Antibiotic Therapeutic Regimensmentioning

confidence: 90%

Section: Antibiotic Therapeutic Regimensmentioning

confidence: 99%

Review article: the global emergence ofHelicobacter pyloriantibiotic resistance

Thung

Aramin

Vavinskaya

et al. 2015

Aliment Pharmacol Ther

619

562

View full text Add to dashboard Cite

show abstract

“…Hybrid therapy combines the sequential and concomitant therapy regimens with seven days of dual therapy (PPI and amoxicillin) followed by seven days of quadruple therapy (a PPI, amoxicillin, clarithromycin and metronidazole) (12). Some studies have reported the seven-day plus seven-day hybrid therapy to achieve high eradication rates (12,13).…”

Section: Introductionmentioning

confidence: 99%

Meta-Analysis of Sequential, Concomitant and Hybrid Therapy for <i>Helicobacter pylori</i> Eradication

Deng

Luo

2015

Intern. Med.

View full text Add to dashboard Cite

Objective To compare the efficacy of sequential therapy, concomitant therapy and hybrid therapy for the treatment of Helicobacter pylori (H. pylori) infection. Methods PubMed, Web of Science, Medline, Embase, the Cochrane Central Register of Controlled Trials and CNKI were searched up to the end of May 10, 2014 in order to identify all randomized controlled trials (RCTs) reporting the effects of sequential therapy, concomitant therapy and hybrid therapy on H. pylori eradication. The relative risk (RR) of eradicating H. pylori infection after sequential therapy compared with concomitant therapy or hybrid therapy was pooled. The eradication rates were considered both on an intention-to-treat (ITT) and per-protocol (PP) basis. Results A total of 10 RCTs involving 3,501 patients were included. The pooled data suggested that the differences between the three groups were not statistically significant (ITT analysis: sequential therapy vs. concomitant therapy: RR=1.01, 95%confidence interval (CI): 0.97-1.04, sequential therapy vs. hybrid therapy: RR=1.02, 95%CI: 0.85-1.22, concomitant therapy vs. hybrid therapy: RR=1.03, 95%CI: 0.97-1.08; PP analysis: sequential therapy vs. concomitant therapy: RR=1.00, 95%CI: 0.96-1.03, sequential therapy vs. hybrid therapy: RR=0.97, 95%CI: 0.86-1.09, concomitant therapy vs. hybrid therapy: RR=1.01, 95%CI: 0.93-1.10). In the ITT and PP analyses, the overall eradication rates were 84.3% (95%CI: 79.1-89.4) and 86.4% (95%CI: 81.7-91.0) for the sequential therapy group, 86.7% (95%CI: 81.0-92.3) and 89.8% (95%CI: 85.1-94.5) for the concomitant therapy group and 86.6% (95%CI: 82.3-91.0) and 92.7% (95%CI: 90.5-94.9) for the hybrid therapy group, respectively. There were no significant differences among these therapies in terms of the rate of side effects. Conclusion The pooled evidence suggests that sequential therapy, concomitant therapy and hybrid therapy are similar with respect to the treatment of H. pylori infection.

show abstract

“…Hybrid therapy combines the sequential and cocomittant therapy regimens with 7 d of dual therapy (PPI and amoxicillin) followed by 7 d of quadruple therapy (a PPI, amoxicillin, clarithromycin and metronidazole) [13]. Some studies have reported this therapy to achieve high eradication rates [13,14].…”

Section: Resultsmentioning

confidence: 99%

Comparison of the efficacy of six different Helicobacter pylori eradication regimens: greater than or equal to another

Sezıklı¹,

Şirin²,

Çetinkaya³

et al. 2018

biomedicalresearch

View full text Add to dashboard Cite

Objective: This study aimed to compare H. pylori eradication rates of different therapy regimens that are commonly used and investigated. Methods: The study included 210 patients with H. pylori positive nonulcer dyspepsia, who were randomised into 6 groups. Group 1: Rabeprazole 20 mg BID+amoxicillin 1000 mg BID for the first 7 d and rabeprazole 20 mg BID+amoxicillin 1000 mg BID+clarithromycin 500 mg BID+metronidazole 500 mg TID for the second 7 d. Group 2: Rabeprazole 20 mg BID+amoxicillin 1000 mg BID for the first 5 d and rabeprazole 20 mg BID+clarithromycin 500 mg BID+metronidazole 500 mg TID for the second 5 d. Group 3: Rabeprazole 20 mg BID+metranidazole 500 mg TID+tetracycline 500 mg QID+bismuth QID for 14 d. Group 4: Rabeprazole 20 mg BID+clarithromycin 500 mg BID+amoxicillin 1000 mg BID for 14 d. Group 5: Rabeprazole 20 mg BID+amoxicillin 1000 mg BID+clarithromycin 500 mg BID +metronidazole 500 mg TID for 7 d. Group 6: Rabeprazole 20 mg BID+amoxicillin 1000 mg BID +clarithromycin 500 mg BID+metronidazole 500 mg TID for 14 d. Results: H. pylori eradication rates were 65.6%, 68.6%, 56.7%, 51.4%, 65.6% and 62.9% respectively, included in the ITT analysis, and 68.6%, 68.6%, 62.9%, 51.4%, 68.6% and 62.9% respectively, included in the PP analysis for all groups. There was no significant difference between the groups with regard to eradication rates. Conclusion: Although H. pylori eradication rates of hybrid, sequential and concomitant therapy regimens were higher than those of quadruple and standard triple therapy regimens, they were also far from the ideal rate.

show abstract

242 14-Day, High-Dose Acid Suppression, Non-Bismuth Quadruple Therapies (Hybrid vs. Concomitant) for Helicobacter pylori Infection: A Randomized Trial

Cited by 6 publications

References 0 publications

Review article: the global emergence ofHelicobacter pyloriantibiotic resistance

Review article: the global emergence ofHelicobacter pyloriantibiotic resistance

Meta-Analysis of Sequential, Concomitant and Hybrid Therapy for <i>Helicobacter pylori</i> Eradication

Comparison of the efficacy of six different Helicobacter pylori eradication regimens: greater than or equal to another

Contact Info

Product

Resources

About